JP2015502352A - 重水素強化ペリリルアルコール、イソペリリルアルコール、及びその誘導体を含む医薬組成物 - Google Patents

重水素強化ペリリルアルコール、イソペリリルアルコール、及びその誘導体を含む医薬組成物 Download PDF

Info

Publication number
JP2015502352A
JP2015502352A JP2014542593A JP2014542593A JP2015502352A JP 2015502352 A JP2015502352 A JP 2015502352A JP 2014542593 A JP2014542593 A JP 2014542593A JP 2014542593 A JP2014542593 A JP 2014542593A JP 2015502352 A JP2015502352 A JP 2015502352A
Authority
JP
Japan
Prior art keywords
deuterium
alcohol
pharmaceutical composition
compound
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014542593A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015502352A5 (enExample
Inventor
チェン、トーマス
レヴィン、ダニエル
プパリ、サティッシュ
Original Assignee
ネオンク テクノロジーズ インク．
ネオンク テクノロジーズ インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/566,731 external-priority patent/US8916545B2/en
Application filed by ネオンク テクノロジーズ インク．, ネオンク テクノロジーズ インク． filed Critical ネオンク テクノロジーズ インク．
Publication of JP2015502352A publication Critical patent/JP2015502352A/ja
Publication of JP2015502352A5 publication Critical patent/JP2015502352A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/05—Alcohols containing rings other than six-membered aromatic rings
    • C07C33/14—Alcohols containing rings other than six-membered aromatic rings containing six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2014542593A 2011-11-21 2012-11-21 重水素強化ペリリルアルコール、イソペリリルアルコール、及びその誘導体を含む医薬組成物 Pending JP2015502352A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161562105P 2011-11-21 2011-11-21
US61/562,105 2011-11-21
US13/566,731 US8916545B2 (en) 2010-08-27 2012-08-03 Pharmaceutical compositions comprising POH derivatives
US13/566,731 2012-08-03
PCT/US2012/066379 WO2013119304A2 (en) 2011-11-21 2012-11-21 Pharmaceutical compositions comprising deuterium-enriched perillyl alcohol, iso-perillyl alcohol and derivatives thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017161091A Division JP2018035148A (ja) 2011-11-21 2017-08-24 重水素強化ペリリルアルコール、イソペリリルアルコール、及びその誘導体を含む医薬組成物

Publications (2)

Publication Number Publication Date
JP2015502352A true JP2015502352A (ja) 2015-01-22
JP2015502352A5 JP2015502352A5 (enExample) 2015-11-26

Family

ID=48948152

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014542593A Pending JP2015502352A (ja) 2011-11-21 2012-11-21 重水素強化ペリリルアルコール、イソペリリルアルコール、及びその誘導体を含む医薬組成物
JP2017161091A Pending JP2018035148A (ja) 2011-11-21 2017-08-24 重水素強化ペリリルアルコール、イソペリリルアルコール、及びその誘導体を含む医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017161091A Pending JP2018035148A (ja) 2011-11-21 2017-08-24 重水素強化ペリリルアルコール、イソペリリルアルコール、及びその誘導体を含む医薬組成物

Country Status (8)

Country Link
EP (1) EP2782894A4 (enExample)
JP (2) JP2015502352A (enExample)
KR (1) KR20150000469A (enExample)
CN (1) CN103946202A (enExample)
BR (1) BR112014012180A2 (enExample)
CA (1) CA2856403A1 (enExample)
HK (1) HK1201253A1 (enExample)
WO (1) WO2013119304A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021512907A (ja) * 2018-02-08 2021-05-20 ネオンク テクノロジーズ インク． 血液脳関門を透過性にする方法
JP7789728B2 (ja) 2018-02-08 2025-12-22 ユニバーシティー オブ サウザン カリフォルニア 血液脳関門を透過性にする方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104945334B (zh) * 2014-03-27 2018-02-16 沈阳药科大学 紫苏醇衍生物及其制备和应用
CN104945333B (zh) * 2014-03-27 2018-02-02 沈阳药科大学 紫苏醇类似物及其制备和应用
CN104945335B (zh) * 2014-03-27 2018-02-16 沈阳药科大学 紫苏胺类化合物及其制备和应用
CN104945336B (zh) * 2014-03-27 2018-02-16 沈阳药科大学 紫苏酸甲酯含氮衍生物及其制备和应用
CN116789530B (zh) * 2023-05-16 2025-12-19 杭州师范大学 一种紫苏醇酚类衍生物及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010065038A (ja) * 2001-03-23 2010-03-25 Luitpold Pharmaceuticals Inc 脂肪アルコール薬物複合体
WO2010091198A1 (en) * 2009-02-06 2010-08-12 University Of Southern California Therapeutic compositions comprising monoterpenes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4272441A (en) * 1980-03-13 1981-06-09 Fmc Corporation Preparation of carbamates
US20060104997A1 (en) * 2001-12-11 2006-05-18 Constantinides Panayiotis P Monoterpene compositions and uses thereof
BR0107262B1 (pt) 2001-12-17 2014-04-22 Da Fonseca Clovis Orlando Pereira Composição farmacêutica inalatória
KR20070051258A (ko) * 2004-06-23 2007-05-17 호프만 로버트 에프 표적화되는 산화적 치료 제형의 화상 치료에서의 용도
US7601355B2 (en) 2005-06-01 2009-10-13 Northwestern University Compositions and methods for altering immune function
EP2081565A2 (en) * 2006-10-13 2009-07-29 Reliance Life Sciences Pvt., Ltd. Cinnamic acid, vanillic acid and benzofuran derivatives for use in the treatment of inflammation and cancer
EP2898883B1 (en) * 2010-08-27 2016-11-23 Neonc Technologies Inc. Pharmaceutical compositions comprising perillyl alcohol carbamates
CN101979378B (zh) * 2010-10-13 2012-06-27 中国科学院上海有机化学研究所 一种手性γ-内酰胺化合物的合成方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010065038A (ja) * 2001-03-23 2010-03-25 Luitpold Pharmaceuticals Inc 脂肪アルコール薬物複合体
WO2010091198A1 (en) * 2009-02-06 2010-08-12 University Of Southern California Therapeutic compositions comprising monoterpenes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEN, HAITAO; CHAN, KENNETH K.: "Synthesis of deuterium labeled perillyl alcohol and dual C-13 and deuterium labeled perillic acid, m", JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, vol. 39(5), JPN6016021945, 1997, pages 369 - 377, ISSN: 0003336391 *
TUNG, ROGER: "The development of deuterium-containing drugs", INNOVATIONS IN PHARMACEUTICAL TECHNOLOGY, vol. 32, JPN6016021947, 2010, pages 26 - 28, ISSN: 0003336392 *
小田切 優樹: "プロドラッグ", 新・ドラッグデリバリーシステム, JPN6016021948, 2000, pages 123 - 126, ISSN: 0003336393 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021512907A (ja) * 2018-02-08 2021-05-20 ネオンク テクノロジーズ インク． 血液脳関門を透過性にする方法
JP7325425B2 (ja) 2018-02-08 2023-08-14 ネオンク テクノロジーズ インク． 血液脳関門を透過性にする方法
JP2023145654A (ja) * 2018-02-08 2023-10-11 ネオンク テクノロジーズ インク． 血液脳関門を透過性にする方法
US12208066B2 (en) 2018-02-08 2025-01-28 University Of Southern California Methods of permeabilizing the blood brain barrier
JP7789728B2 (ja) 2018-02-08 2025-12-22 ユニバーシティー オブ サウザン カリフォルニア 血液脳関門を透過性にする方法

Also Published As

Publication number Publication date
JP2018035148A (ja) 2018-03-08
WO2013119304A2 (en) 2013-08-15
BR112014012180A2 (pt) 2017-05-30
KR20150000469A (ko) 2015-01-02
WO2013119304A3 (en) 2013-10-03
EP2782894A4 (en) 2015-03-11
CN103946202A (zh) 2014-07-23
EP2782894A2 (en) 2014-10-01
CA2856403A1 (en) 2013-08-15
HK1201253A1 (en) 2015-08-28

Similar Documents

Publication Publication Date Title
JP6431009B2 (ja) Ｐｏｈ誘導体を含む医薬組成物
JP6122564B2 (ja) イソペリリルアルコールの使用方法および装置
JP6674957B2 (ja) ペリリルアルコール誘導体を含む医薬組成物
JP2018035148A (ja) 重水素強化ペリリルアルコール、イソペリリルアルコール、及びその誘導体を含む医薬組成物
US20230145207A1 (en) Pharmaceutical compositions comprising poh derivatives and methods of use
EP3806838A1 (en) Pharmaceutical compositions comprising poh derivatives
HK1188984B (zh) 使用异紫苏醇的方法和装置

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151005

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151005

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160614

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20161111

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170425